Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boryung Pharmaceuticals Co. Ltd.

www.boryung.co.kr/

Latest From Boryung Pharmaceuticals Co. Ltd.

Oncology, Diabetes Dominate Korean Out-Licensing But Deals And Value Decline

Scrip takes a look at how the South Korean pharma/biotech industry's cross-border deals over the past few years compare with global trends, finding that oncology and diabetes have been the dominant therapeutic areas for the out-licensing of assets, but recent activity and value have declined from a peak in 2015.

South Korea Commercial

Korea Stepping Up IO R&D To Catch Up With Global Players, Trends

Immuno-oncology deals and R&D by South Korean companies are picking up speed as they are put more focus on the hot sector in line with global trends.

Commercial ImmunoOncology

Deal Watch: Boehringer’s Hectic Stretch Adds Up To Five Deals

Following its partnership with Dicerna, the German pharma signs a second NASH deal with MiNA and inks three cancer-related transactions, including divestitures. Also, Amgen buys out Kirin’s half of their joint venture for $780m.

Deals M & A

Deal Watch: Takeda Seeks A Crescendo With Collaboration On New Type Of Cancer Compound

AstraZeneca concludes week of four out-licensing transactions by selling US rights to Toprol XL to Aralez and ex-US rights to Rhinocort Aqua to J&J. Molecular Partners gets back rights to an IL-13/IL-17 inhibitor for pulmonary indications after a 2011 deal with Janssen unravels.

Deals M & A
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Gastrointestinal
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Boryung Pharmaceuticals Co. Ltd.
  • Senior Management
  • Tae-Hong Choi, CEO
  • Contact Info
  • Boryung Pharmaceuticals Co. Ltd.
    Phone: (82)
    Cheonggyeonggung-ro 136
    Jongro-gu
    Seoul, 110-750
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register